CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, an emerging leader in the development of innovative gene therapies for severe genetic disorders, today announced the appointment of Alexandre P. LeBeaut, M.D., as chief medical officer. Dr. LeBeaut has more than 20 years of industry experience working with specialty pharmaceutical companies.
